[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620954":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":62,"collaborators":30,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":30,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":46,"whyStopped":30,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"China Medical University Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"omega-3 fatty acids: EPA","ACTIVE_COMPARATOR","EPA",[13],"Dietary Supplement: Omega-3",{"label":15,"type":10,"description":16,"interventionNames":17},"omega-3 fatty acids: DHA","DHA",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"placebo","PLACEBO_COMPARATOR","olive oil",[23],"Dietary Supplement: Placebo",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIETARY_SUPPLEMENT","Omega-3","EPA or DHA",[15,9],null,{"type":26,"name":32,"description":21,"armGroupLabels":33,"otherNames":30},"Placebo",[19],[35],{"name":36,"affiliation":5,"role":37},"Pei-Chen Chang, PhD","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+88622052121","14126","013121@tool.caaumed.org.tw",[45],{"facility":5,"status":46,"city":47,"state":30,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Taichung","404","Taiwan","TW",{"type":52,"coordinates":53},"Point",[54,55],120.6839,24.1469,{"lat":55,"lon":54},[58,60],{"name":36,"role":40,"phone":59,"phoneExt":30,"email":43},"886 4 22052121",{"name":61,"role":37,"phone":30,"phoneExt":30,"email":30},"Pei-chen Chang, PD",{"type":37,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Pei-Chen Chang","Director of Child Psychiatry Division","100620954","omega-3-fatty-acids-neuroendocrine-and-attention-deficit-hyperactivity-disorder-omneadhd-100620954",false,"NCT07364331","Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)","Omega- 3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder With (OMNeADHD) A Double Blind Randomized Controlled Trial of High Dose Omega- 3 Fatty Acids in Children and Adolescents With ADHD With Omega- 3 Deficiency.","OMNeADHD","Inclusion Criteria:\n\n1. DSM-5 diagnosis of ADHD\n2. Did not have any changes of ADHD treatment (pharmacological\u002Fpsychological) within 4 weeks of entering the trial.\n3. SNAP-IV inattention subscale \\>=12, or hyperactivity subscale \\>=12, or inattention+ hyperactivity subscales \\>=24\n\nExclusion Criteria:\n\n1. IQ\\\u003C80\n2. Allergic to omega-3\n3. Physical disorders: thyroid function, cancer\n4. Psychiatric comorbidity: SUD, psychotic disorders, bipolar disorder, major depressive disorder","ALL","6 Years","18 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"NA","This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.",[84,85,86],"ADHD","Children","Adolescents",[88,89,90,91,84,92],"omega-3","epa","dha","children","adolescents","2026-01-22",{"date":95,"type":96},"2026-01-26","ACTUAL",{"date":98,"type":96},"2021-09-04",{"date":100,"type":78},"2026-07-31",{"name":5,"class":6},1]